LAQUINIMOD IMMUNOMODULATORY ACTION CONFERS BOTH NEUROPROTECTIVE AND
ANTI-INFLAMMATORY PROPERTIES

(Thomson Reuters ONE) - Results Presented at 25th Congress of the European Committee forTreatment and Research in Multiple Sclerosis (ECTRIMS)Jerusalem, Israel and Lund, Sweden, September 11, 2009 - TevaPharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech(NASDAQ OMX NORDIC: ACTI) today presented data further illuminatingthe novel, dual mechanism of action (MOA) of investigational oral,once-daily, laquinimod for the treatment of relapsing-remittingmultiple sclerosis (RRMS), conferring neuroprotective andanti-inflammatory properties. Results from several preclinicalstudies suggest that laquinimod elicits a protective therapeuticeffect by reducing demyelination and inducing axonal protection.Read the complete press release below.Contact: Elana Holzman Teva Pharmaceutical +972-(3)-926-7554 Kevin Mannix Industries Ltd. +1-(215)-591-8912 Teva North America Tomas Leanderson Active Biotech AB +46-46-19-20-95 Göran Forsberg Active Biotech AB +46-46-19-11-54http://hugin.info/1002/R/1340862/320555.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 11.09.2009 - 15:30 Uhr
Sprache: Deutsch
News-ID 5724
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 303 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"LAQUINIMOD IMMUNOMODULATORY ACTION CONFERS BOTH NEUROPROTECTIVE AND
ANTI-INFLAMMATORY PROPERTIES"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech